Free shipping on all orders over $ 500

ZM 306416

Cat. No. M3139

All AbMole products are for research use only, cannot be used for human consumption.

ZM 306416 Structure
Synonym:

CB 676475

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 70 In stock
10mg USD 110 In stock
25mg USD 240 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of <10 nM.

Customer Product Validations & Biological Datas
Source J Biomol Screen (2012). Figure 6. ZM 306416
Method Assessment of the anti-proliferative effects of hits against a panel of established cell lines
Cell Lines EGFR cell lines A549 and H2030
Concentrations 10 μM
Incubation Time -
Results Confirming the newly identified inhibitory activity of ZM-306416 toward EGFR, this compound induced selective anti-proliferative effect toward the EGFR addicted NSCLC cell lines H3255 and HCC4011, while sparing the wild type EGFR cell lines A549 and H2030.
Chemical Information
Molecular Weight 333.74
Formula C16H13ClFN3O2
CAS Number 690206-97-4
Solubility (25°C) DMSO 47 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Wei-Bin Wu, et al. Decreased PGF may contribute to trophoblast dysfunction in fetal growth restriction

[2] Christophe Antczak, et al. A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery

Related VEGFR/PDGFR Products
Ramucirumab

Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D).

ABT-869

ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR.

Tivozanib (AV-951)

Tivozanib (AV-951) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively.

Axitinib

Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit.

Regorafenib

Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: ZM 306416, CB 676475 supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.